Comparison of Pharmacokinetic (PK) and Pharmacodynamic(PD) of Biocon Insulin 70/30 and Humulin® 70/30

Phase 1 Completed 78 enrolled Biocon Limited Profil Institut für Stoffwechselforschung GmbH · collab

RandomizedCrossoverDouble-blindOther

Summary

Two-centre, randomised, double-blind, single dose, two-treatment, two-period, two sequence, crossover, 24-hour euglycaemic glucose clamp trial in healthy subjects.

Timeline

Start: 2019-06-15
Primary completion: 2020-01-20
Completion: 2020-01-27

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Biocon Insulin 70/30	Protein / enzyme biologic	0.4 iu/kg	Subcutaneous
Comparator	Humulin ®70/30	Protein / enzyme biologic	0.4 iu/kg	Subcutaneous

Indications

No indication recorded.